| PATENT REGISTER | |||||||||||||||||||||||||
| A Supplementary Protection Certificate (SPC) exists for this Patent. To view the SPC Details click following SPC number(s): 2017/032 | |||||||||||||||||||||||||
| Status | Granted | Patent No. | 2288610 | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Application No. | 09718650.6 | Date of Filing | 10/03/2009 | ||||||||||||||||||||||
| Date Grant Published | 31/08/2016 | Application Published | 02/03/2011 | ||||||||||||||||||||||
| Title of Invention | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | ||||||||||||||||||||||||
| Priority |
|
||||||||||||||||||||||||
| Inventors |
RODGERS, James, D. SHEPARD, Stacey LI, Yun-Long ZHOU, Jiacheng LIU, Pingli MELONI, David XIA, Michael |
||||||||||||||||||||||||
| Current Proprietor |
Incyte Holdings Corporation 1801 Augustine Cut-Off Wilmington, DE 19803 UNITED STATES OF AMERICA |
||||||||||||||||||||||||
| Address for service |
FRKelly Waterways House Grand Canal Quay Dublin D02 PD39 IRELAND |
||||||||||||||||||||||||
| Renewal Fees |
|
||||||||||||||||||||||||
| Publication Language | English | ||||||||||||||||||||||||
| Translation Received Date | |||||||||||||||||||||||||
| 13/09/2016 | Address for Service recorded as FRKelly, 27 Clyde Road, Ballsbridge, Dublin 4, Ireland received on 12/09/2016. | ||||||||||||||||||||||||
| 13/10/2016 | Correction of Patent Specification on 12/10/2016 (B8) | ||||||||||||||||||||||||
| 24/07/2017 | Request for grant a Supplementary Protection Certificate, citing Patent number 2288610 as the relevant basic patent, in respect of the product Baracitinib and pharmaceutically acceptable salts thereof. filed on 20/07/2017. Reference number of request is 2017/032. | ||||||||||||||||||||||||
| 04/09/2018 | Supplementary Protection Certificate Number 2017/032, having an expiry date of 14/02/2032 granted on 04/09/2018. | ||||||||||||||||||||||||
